TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25564250

Group type: EXPERIMENTAL
Intervention: EE audio program and discussion guide
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 264
Study: 24249423

Group type: EXPERIMENTAL
Intervention: Hexaminolevulinate (HAL) instillation before surgery with blue-light cystoscopy (BL group)
Number of subjects: 130

Group type: COMPARATOR
Intervention: White-light cystoscopy (WL group)
Number of subjects: 130
Study: 22119997

Group type: EXPERIMENTAL
Intervention: Health care practitioners during pregnancy
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Health care practitioners at school age
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Parents during pregnancy
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Parents at school age
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Friends and relatives at school age
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Internet at school age
Number of subjects: 649
Study: 19123151

Group type: EXPERIMENTAL
Intervention: Bimatoprost/timolol fixed combination (BTFC)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Latanoprost/timolol fixed combination (LTFC)
Number of subjects: 82
Study: 17512721

Group type: EXPERIMENTAL
Intervention: CMFx6 or 7
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Temporary amenorrhea
Number of subjects: 767

Group type: COMPARATOR
Intervention: No CT
Number of subjects: 767
Study: 15451336

Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol (misoprostol administered 6-8 hours vs. 23-25 hours after mifepristone)
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol (when both clinician and patient felt the gestational sac had passed)
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol (overall sensitivity, specificity, and predictive values)
Number of subjects: 931
Study: 11553119

Group type: EXPERIMENTAL
Intervention: Household cleansing solutions adjusted to pH 7.4
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Household cleansing solutions adjusted to pH 10.0
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Household cleansing solutions adjusted to pH 10.8
Number of subjects: 30
Study: 9716580

Group type: EXPERIMENTAL
Intervention: 100 microgram/kg BB-10010
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 30 microgram/kg BB-10010
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no BB-10010)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BB-10010 (both dosages)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BB-10010
Number of subjects: 30
Study: 8014642

Group type: EXPERIMENTAL
Intervention: Fixed low-dose warfarin (2 mg/d)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Adjusted higher-dose warfarin
Number of subjects: 96
Study: 2685260

Group type: EXPERIMENTAL
Intervention: Fixed Partial Dentures (FPDs)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Removable Partial Dentures (RPDs)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Fixed Partial Dentures (FPDs) excluding early failures
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Kennedy class II patients with Fixed Partial Dentures (FPDs)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Radiographic assessments of implants
Number of subjects: 232
Study: 4204541

Group type: EXPERIMENTAL
Intervention: Rifampin and isoniazid regimen
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Rifampin, isoniazid, and ethambutol regimen
Number of subjects: 632

Group type: COMPARATOR
Intervention: Control regimen (streptomycin, isoniazid, and ethambutol)
Number of subjects: 632
Study: 31924224

Group type: EXPERIMENTAL
Intervention: Robotic exoskeleton over-ground training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care walking training (including body-weight supported treadmill training, overground training, stationary robotic systems)
Number of subjects: 0
Study: 28543566

Group type: EXPERIMENTAL
Intervention: App
Number of subjects: 220

Group type: COMPARATOR
Intervention: Booklet
Number of subjects: 220
Study: 26481821

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg monthly (frequent regimen; n = 102)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 or 0.5 mg quarterly (infrequent regimen; n = 217)
Number of subjects: 353
Study: 24344871

Group type: EXPERIMENTAL
Intervention: Reading acceleration program
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Combination of reading acceleration and WM training
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Reading-acceleration-alone group
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: WM-program-followed-by-reading-acceleration group
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study: 22431170

Group type: EXPERIMENTAL
Intervention: Bicalutamide (anti-androgen)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Goserelin (GnRH agonist)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Endocrine therapy (Bicalutamide and Goserelin)
Number of subjects: 28
Study: 20159209

Group type: EXPERIMENTAL
Intervention: Cognitive-behaviorally based self‐help book for tinnitus
Number of subjects: 162

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 162
Study: 18088057

Group type: EXPERIMENTAL
Intervention: Doppler sonography (DUS) examination of major abdominal arteries
Number of subjects: 29
Study: 15502600

Group type: EXPERIMENTAL
Intervention: d‐MPH
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: d,l‐MPH
Number of subjects: 132

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 132
Study: 11170909

Group type: EXPERIMENTAL
Intervention: Dextran
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Gelatin
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 230

Group type: COMPARATOR
Intervention: Colloid group (Dextran and Gelatin)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Crystalloid group (Lactated Ringer's and Normal saline)
Number of subjects: 230
Study: 9540946

Group type: EXPERIMENTAL
Intervention: 450 mg linoleic acid and 600 mg calcium
Number of subjects: 86

Group type: COMPARATOR
Intervention: 450 mg starch and 600 mg lactose placebo
Number of subjects: 86
Study: 8007591

Group type: EXPERIMENTAL
Intervention: Methylprednisolone and chlorambucil (MP+Ch)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Methylprednisolone (MP)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 2
Study: 2689470

Group type: EXPERIMENTAL
Intervention: Meptazinol 50 mg
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Meptazinol 100 mg
Number of subjects: 117

Group type: COMPARATOR
Intervention: Morphine 5 mg
Number of subjects: 117

Group type: COMPARATOR
Intervention: Morphine 10 mg
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 117
Study: 30444691

Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation (n=14)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Dycal (calcium hydroxide cement; n=14)
Number of subjects: 17
Study: 28679020

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg administered with food (evening meal for AF, morning meal for DVT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg administered with food
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivaroxaban 20 mg administered with evening meal (AF population)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivaroxaban 20 mg administered with morning meal (DVT population)
Number of subjects: 0
Study: 25034935

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine 0.5 mg.kg‐1 (S+K group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 5% lidocaine 1.5 mg.kg‐1 (L5% group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Adrenaline 15μg (ADR group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physiological saline 3 ml (SF group; control group)
Number of subjects: 80
Study: 24151326

Group type: COMPARATOR
Intervention: Standard dose of 25 to 30 minutes of aerobic exercise (STAN)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Higher dose of 50 to 60 minutes of aerobic exercise (HIGH)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Combined dose of 50 to 60 minutes of aerobic and resistance exercise (COMB)
Number of subjects: 301
Study: 21218090

Group type: EXPERIMENTAL
Intervention: Ginger (1.2 g)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 19388899

Group type: EXPERIMENTAL
Intervention: 5 mg hyperbaric bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 5 mg hyperbaric bupivacaine with 15 microg of clonidine
Number of subjects: 60
Study: 16962532

Group type: EXPERIMENTAL
Intervention: Continuous Knotless Technique (CKT)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Interrupted Technique (IT)
Number of subjects: 214
Study: 14985138

Group type: EXPERIMENTAL
Intervention: 0.17 l of water every 1/2 hour
Number of subjects: 4

Group type: COMPARATOR
Intervention: 0.6 l of water every 1/2 hour
Number of subjects: 4
Study: 10887323

Group type: EXPERIMENTAL
Intervention: Open food challenges (OFCs) followed by double-blind, placebo-controlled food challenges (DBPCFCs) with Rosaceae foods
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Skin prick tests and CAP System (FEIA) with Rosaceae foods
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Skin prick tests and CAP System (FEIA)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Systematic challenges including OFC and DBPCFC
Number of subjects: 34
Study: 9594556

Group type: EXPERIMENTAL
Intervention: Slow-release nicotinic acid (KN-SR)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Ordinary form of nicotinic acid (KN)
Number of subjects: 136
Study: 7506174

Group type: EXPERIMENTAL
Intervention: nimesulide (50mg twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 3450524

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 20
Study: 31222915

Group type: EXPERIMENTAL
Intervention: Supervised teaching and personalized feedback
Number of subjects: 15
Study: 30348154

Group type: EXPERIMENTAL
Intervention: 10% beta-cyfluthrin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10% beta-cyfluthrin treated inserts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluorescent dust treated inserts
Number of subjects: 0
Study: 27043667

Group type: EXPERIMENTAL
Intervention: Icodextrin solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: 1.5% glucose-based biocompatible neutral pH solution
Number of subjects: 100
Study: 24517583

Group type: EXPERIMENTAL
Intervention: Multicomponent strategy to reduce physical restraint use (including development of opinion leaders, education and training of physicians and nurses, implementation of least restraint rounds)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multicomponent strategy to reduce physical restraint use
Number of subjects: 0
Study: 22449831

Group type: EXPERIMENTAL
Intervention: GB retrieval through umbilical port
Number of subjects: 120

Group type: COMPARATOR
Intervention: GB retrieval through epigastric port
Number of subjects: 120
Study: 19439284

Group type: EXPERIMENTAL
Intervention: Uterine cavity injection of day 2 embryo culture supernatant before day 3 embryo transfer
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 90
Study: 18308656

Group type: EXPERIMENTAL
Intervention: Basal-bolus insulin regimen (0.5 U/kg total daily dose: 0.25 U/kg insulin glargine and 0.25 U/kg divided into 3 mealtime doses)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Historical control group (standard care)
Number of subjects: 26
Study: 15026400

Group type: EXPERIMENTAL
Intervention: Iontophoretic fentanyl hydrochloride (40-microg infusion over 10 minutes)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Intravenous morphine (1-mg bolus every 5 minutes; maximum of 10 mg/h)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Iontophoretic fentanyl hydrochloride
Number of subjects: 636

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 636
Study: 11393871

Group type: EXPERIMENTAL
Intervention: Prison-based residential drug treatment
Number of subjects: 2315
Study: 9258175

Group type: EXPERIMENTAL
Intervention: GAX 65
Number of subjects: 18

Group type: COMPARATOR
Intervention: GAX 35
Number of subjects: 18
Study: 8485309

Group type: COMPARATOR
Intervention: Fine needle aspiration (FNA) cytology without clinical information
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fine needle aspiration (FNA) cytology with clinical information
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Interobserver variability
Number of subjects: 80
Study: 3333524

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg daily
Number of subjects: 14
Study: 31261214

Group type: EXPERIMENTAL
Intervention: Pain during training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pain-free controls
Number of subjects: 0
Study: 30380535

Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Verbal Restructuring (VR)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Waitlist Control (WC)
Number of subjects: 58
Study: 26941050

Group type: EXPERIMENTAL
Intervention: Cigarette substitute that does not produce an inhalable aerosol
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: ECIG with 0 mg/ml nicotine concentration
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: ECIG with 8 mg/ml nicotine concentration
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: ECIG with 36 mg/ml nicotine concentration
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: All ECIG conditions (0, 8, 36 mg/ml)
Number of subjects: 520
Study: 24151956

Group type: COMPARATOR
Intervention: Soccer Group (SG)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Zumba Group (ZG)
Number of subjects: 107
Study: 23205376

Group type: EXPERIMENTAL
Intervention: Simulated clinics with actor-patients (24 simulated consultations over four days)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Community-based attachments with real patients (four days with community-based general practitioners)
Number of subjects: 128
Study: 19401423

Group type: EXPERIMENTAL
Intervention: Elevated free fatty acids (FFAs)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemia
Number of subjects: 21

Group type: COMPARATOR
Intervention: Rosiglitazone treatment
Number of subjects: 21
Study: 17181396

Group type: EXPERIMENTAL
Intervention: Exercise and calcium (Ex+Ca)
Number of subjects: 88

Group type: COMPARATOR
Intervention: No effect
Number of subjects: 88
Study: 15267039

Group type: EXPERIMENTAL
Intervention: Body diagrams
Number of subjects: 300

Group type: COMPARATOR
Intervention: No body diagram
Number of subjects: 300
Study: 10772502

Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline 500 mg administered 45 minutes prior to SWL
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not treated with aminophylline)
Number of subjects: 10
Study: 9308788

Group type: EXPERIMENTAL
Intervention: Group 1 (long distance oocyte transport)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Group 2 (no long distance transport)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Group 2
Number of subjects: 100
Study: 8327918

Group type: EXPERIMENTAL
Intervention: Support groups for widows
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no support groups)
Number of subjects: 0
Study: 3537248

Group type: EXPERIMENTAL
Intervention: Vaccine virus at 10(7) TCID50/ml
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Vaccine virus at 10(8) TCID50/ml
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both vaccine groups (10(7) and 10(8) TCID50/ml)
Number of subjects: 54
Study: 29752170

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) for sleep disordered breathing; mean duration 89 ± 62 days
Number of subjects: 9
Study: 27992863

Group type: EXPERIMENTAL
Intervention: Statin plus fenofibrate treatment in patients without CKD
Number of subjects: 5464

Group type: COMPARATOR
Intervention: Statin plus fenofibrate treatment in patients with CKD
Number of subjects: 5464
Study: 25611084

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg BIW
Number of subjects: 287

Group type: COMPARATOR
Intervention: Etanercept 50 mg QW plus topical therapies
Number of subjects: 287
Study: 23224792

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg once a day, rabeprazole 20 mg twice a day, and tinidazole 500 mg twice daily for 7 days followed by rabeprazole 20 mg OD for 8 weeks
Number of subjects: 131
Study: 21206488

Group type: EXPERIMENTAL
Intervention: Physical activity group (instructed by a physiotherapist to increase physical activity)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (instructed to maintain lifestyle)
Number of subjects: 102
Study: 18495885

Group type: EXPERIMENTAL
Intervention: Glutamate antagonists (caroverine and ketamine) administered during sleep
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16894939

Group type: EXPERIMENTAL
Intervention: Ureaplasma urealyticum infection
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis infection
Number of subjects: 28
Study: 12657228

Group type: EXPERIMENTAL
Intervention: ICBN preservation
Number of subjects: 73

Group type: COMPARATOR
Intervention: ICBN division
Number of subjects: 73
Study: 10709804

Group type: EXPERIMENTAL
Intervention: Birth and death urn with immigration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized version of Polya's urn
Number of subjects: 0

Group type: COMPARATOR
Intervention: Four adaptive randomization models
Number of subjects: 0
Study: 9170519

Group type: EXPERIMENTAL
Intervention: Low-dose MPA (600 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: High-dose MPA (1,200 mg/day)
Number of subjects: 35
Study: 8253229

Group type: EXPERIMENTAL
Intervention: Intermittent pilocarpine drop medication (2%)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous low-dose pilocarpine delivery by a membrane-controlled Ocusert unit (P40)
Number of subjects: 30
Study: 31324831

Group type: EXPERIMENTAL
Intervention: Dobutamine (5, 10, 20 μg/kg.min)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 34
Study: 29068453

Group type: EXPERIMENTAL
Intervention: SFA high‐fat meal with orange juice (500 ml)
Number of subjects: 55

Group type: COMPARATOR
Intervention: SFA high‐fat meal with water (control)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: MUFA high‐fat meal with orange juice (500 ml)
Number of subjects: 55

Group type: COMPARATOR
Intervention: MUFA high‐fat meal with water (control)
Number of subjects: 55
Study: 26846284

Group type: EXPERIMENTAL
Intervention: Luseogliflozin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 24342143

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 2783

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 2783

Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 2783
Study: 22994024

Group type: COMPARATOR
Intervention: Normal saline 2 ml (Group I)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg (Group II)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg (Group III)
Number of subjects: 105
Study: 19838814

Group type: EXPERIMENTAL
Intervention: 3.5 h skills training plus 30 min of skills testing
Number of subjects: 89

Group type: COMPARATOR
Intervention: 4 h practice-only control course
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Testing as a final activity in a CPR skills course
Number of subjects: 89
Study: 18596740

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study: 15768181

Group type: EXPERIMENTAL
Intervention: Intensive preoperative teaching with two visits using audiovisual aids
Number of subjects: 42
Study: 12451077

Group type: EXPERIMENTAL
Intervention: Workshop exposure
Number of subjects: 87

Group type: COMPARATOR
Intervention: Nonexposed physicians
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Exposed physicians
Number of subjects: 87
Study: 10929726

Group type: EXPERIMENTAL
Intervention: Standardized pain therapy with tramadol and diclofenac
Number of subjects: 60

Group type: COMPARATOR
Intervention: No standardized pain therapy
Number of subjects: 60
Study: 8523873

Group type: EXPERIMENTAL
Intervention: Duraflo II heparin-treated circuits
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nontreated circuits
Number of subjects: 14
Study: 1742223

Group type: EXPERIMENTAL
Intervention: Folinic acid (FA) + 5-fluorouracil (5-FU) (200 mg/sqm i.v. x 5 days + 400 mg/sqm i.v. in 15' x 5 days every 4 weeks)
Number of subjects: 182

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) alone (400 mg/sqm i.v. in 15' x 5 days every 4 weeks)
Number of subjects: 182
Study: 6972018

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Triple sulfa cream
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 96
Study: 30448484

Group type: EXPERIMENTAL
Intervention: Deep hypothermic circulatory arrest with retrograde cerebral perfusion (DHCA+RCP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Moderate hypothermic circulatory arrest with antegrade cerebral perfusion (MHCA+ACP)
Number of subjects: 20
Study: 28731951

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 80

Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 80
Study: 26304886

Group type: EXPERIMENTAL
Intervention: Lenalidomide alone (15 mg per day on days 1 to 21, followed by 7 days of rest in cycle 1; then 20 mg per day on days 1 to 21, followed by 7 days of rest in cycles 2 to 12)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus Rituximab (LR) (Rituximab 375 mg/m2 weekly for 4 weeks; Lenalidomide as above)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (Rituximab alone)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 91